Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANHPVAX Phase 1 Trial in Healthy Volunteers
NCT05208710Phase 1Recruiting
- Sponsor
- German Cancer Research Center
- Start
- Nov 2022
- Primary completion
- Dec 2027
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of PANHPVAX in human papillomavirus infection (3 arms), sponsored by German Cancer Research Center. Primary endpoint: Frequency and severity of local and systemic reactions at 3 months. Started Nov 2022; status: recruiting.
02
Drugs
PANHPVAX
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT05208710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05208710.